Inflammatory bowel disease and cancer

Area of Science:

• Gastroenterology
• Oncology
• Molecular Pathology

Background:

• Colorectal cancer (CRC) poses a significant clinical challenge for individuals with inflammatory bowel disease (IBD), specifically ulcerative colitis and Crohn's disease.
• Traditional risk factors for CRC in IBD include disease duration and extent, but emerging factors like primary sclerosing cholangitis, folate deficiency, and family history are crucial for risk stratification.

Purpose of the Study:

• To review the risk factors, molecular pathogenesis, and surveillance strategies for colitis-associated colorectal cancer.
• To highlight the importance of early detection and improved risk stratification in managing CRC in IBD patients.

Main Methods:

• Literature review of traditional and novel risk factors for CRC in IBD.
• Analysis of molecular pathogenesis, comparing IBD-associated CRC with sporadic CRC.
• Evaluation of clinical studies on colonoscopic surveillance efficacy and proposed strategies.

Main Results:

• Long disease duration and extent are key risk factors, complemented by primary sclerosing cholangitis, folate deficiency, and family history.
• Molecular pathways in IBD-associated CRC share similarities with sporadic CRC but exhibit distinct temporal alterations.
• Molecular markers show potential for complementing dysplasia detection.
• Colonoscopic surveillance facilitates early cancer detection and may reduce mortality.

Conclusions:

• Refined risk stratification using both traditional and novel factors is essential for CRC management in IBD.
• Understanding the molecular pathogenesis aids in identifying potential biomarkers.
• A structured colonoscopic surveillance strategy is recommended to improve outcomes for IBD patients at risk of CRC.